Quantcast

LogicBio Therapeutics Appoints Richard Moscicki, M.D., and Michael Wyzga to Board of Directors

By GlobeNewswire,  December 06, 2018, 08:00:00 AM EDT


CAMBRIDGE, Mass., Dec. 06, 2018 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc.  (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases, today announced the appointment biopharmaceutical industry leaders Richard Moscicki, M.D. and Michael Wyzga to its Board of Directors. The two are accomplished leaders in the field and individually have decades of strategic and operational management experience. Both have extensive knowledge of rare disease drug development and bring rich insight in the areas of clinical research, regulatory affairs and corporate governance to the board.

"Richard and Michael bring tremendous value and expertise to our board, and we're delighted to be able to draw on their insights as we move toward the clinic in our first indication, the rare genetic disorder methylmalonic acidemia," said Frederic Chereau, LogicBio's President and Chief Executive Officer.

Dr. Moscicki has more than 25 years of experience in drug development and is currently the Executive Vice President for Science and Regulatory Advocacy and the Chief Medical Officer at Pharmaceutical Research and Manufacturers of America (PhRMA). Previously, Dr. Moscicki served as Chief Medical Officer at Genzyme Corporation, where he was responsible for worldwide global regulatory and pharmacovigilance matters, as well as all aspects of clinical research and medical affairs. He also served as a Senior Vice President and Head of Clinical Development at Sanofi-Genzyme. Most recently, from 2013 - 2017, Dr. Moscicki served as Deputy Center Director for Science Operations for the U.S. Food and Drug Administration's Center for Drug Evaluation and Research. Dr. Moscicki holds an M.D. and a B.S. from Northwestern University and is board certified in internal medicine, diagnostic and laboratory immunology, and allergy and immunology. He completed his residency and fellowship at Massachusetts General Hospital (MGH) and remained on staff at MGH and on the faculty of Harvard Medical School from 1979 to 2013.

"LogicBio's novel approach to genome editing has great potential for delivering corrective genes to patients with rare genetic disorders," said Dr. Moscicki. "I am looking forward to joining the Board of Directors to help the team bring new therapies forward."

Michael Wyzga is a leader in the biotech community and joins LogicBio's Board of Directors as the chair of the audit committee. Currently, Mr. Wyzga is the CEO and President of MSW Consulting, Inc., a private biotechnology consulting firm. Before founding his own strategic consulting firm, Michael Wyzga served as President, CEO and a member of the Board of Directors of Radius Health, Inc. (NASDAQ:RDUS). Before that, he served as CFO and Executive Vice President of Genzyme Corporation for 12 years. Prior to joining Genzyme, Mr. Wyzga served in various senior-level positions in the tech industry, including at Lotus Development and Digital Equipment Company. He has served on the Board of Directors and as chair of the audit committee at several biotechnology companies including OncoMed Pharmaceuticals, Prosensa Holding, Akebia and Idenix Pharmaceuticals. Mr. Wyzga is currently a director at Exact Sciences Corporation, and the Board Chair at X4 Biosciences and GenSIght Biologics. He holds an MBA from Providence College and a B.S. from Suffolk University.

"I am excited for the opportunity to join the LogicBio board and help the company achieve its mission of bringing life-changing therapies to young patients with rare genetic diseases," said Mr. Wyzga.

About LogicBio Therapeutics

LogicBio Therapeutics is a genome editing company focused on developing medicines to durably treat rare diseases in patients with significant unmet medical needs using, GeneRide™, its proprietary technology platform. GeneRide™ enables the site-specific integration of a therapeutic transgene in a nuclease-free and promotorless approach by relying on the native process of homologous recombination to drive lifelong expression. Headquartered in Cambridge, Mass., LogicBio is committed to developing medicines that will transform the lives of pediatric patients and their families.

For more information, please visit www.logicbio.com.

Contacts:

Investors:

Michael Schaffzin

Stern Investor Relations

michael@sternir.com

212-362-1200

Media:

Stephanie Simon, Ten Bridge Communications

Stephanie@Tenbridgecommunications.com

617-581-9333

Source: LogicBio Therapeutics

This article appears in: News Headlines

Referenced Stocks: LOGC, RDUS








Today's Market Activity

NASDAQ 7070.10
49.58  ▲  0.71%
DJIA 24470.14
46.88  ▲  0.19%
S&P 500 2650.79
13.07  ▲  0.50%
Data as of Dec 11, 2018 | 11:37AM